Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark M Awad

Showing results (191-200 of 210) with videos related to

Pageof 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobaccoEleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.
The New England Journal of Medicine|June 23, 2021
Acquired Resistance to KRAS<sup>G12C</sup> Inhibition in CancerMark M Awad, Shengwu Liu, Igor I Rybkin, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humansAya Ludin, Georgia L Stirtz, Asaf Tal, et al.
JAMA Oncology|June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
Cancer Discovery|April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET InhibitorsFederica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Nature Medicine|February 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trialBenjamin Besse, Elvire Pons-Tostivint, Keunchil Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2017
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET RegistryOliver Gautschi, Julie Milia, Thomas Filleron, et al.
Cancer Discovery|March 12, 2021
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular PlasticityNavin R Mahadevan, Erik H Knelson, Jacquelyn O Wolff, et al.
Cancer Cell|January 15, 2020
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic PathwayKari J Kurppa, Yao Liu, Ciric To, et al.
Nature Genetics|April 6, 2023
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerArvind Ravi, Matthew D Hellmann, Monica B Arniella, et al.
Pageof 21

Showing results (191-200 of 210) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobaccoEleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.
The New England Journal of Medicine|June 23, 2021
Acquired Resistance to KRAS<sup>G12C</sup> Inhibition in CancerMark M Awad, Shengwu Liu, Igor I Rybkin, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humansAya Ludin, Georgia L Stirtz, Asaf Tal, et al.
JAMA Oncology|June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
Cancer Discovery|April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET InhibitorsFederica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Nature Medicine|February 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trialBenjamin Besse, Elvire Pons-Tostivint, Keunchil Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2017
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET RegistryOliver Gautschi, Julie Milia, Thomas Filleron, et al.
Cancer Discovery|March 12, 2021
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular PlasticityNavin R Mahadevan, Erik H Knelson, Jacquelyn O Wolff, et al.
Cancer Cell|January 15, 2020
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic PathwayKari J Kurppa, Yao Liu, Ciric To, et al.
Nature Genetics|April 6, 2023
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerArvind Ravi, Matthew D Hellmann, Monica B Arniella, et al.
Pageof 21